Proton Collaborative Group
10
6
9
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
1 terminated/withdrawn out of 10 trials
0.0%
-86.5% vs industry average
30%
3 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Role: lead
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Role: lead
Registry Study for Radiation Therapy Outcomes
Role: lead
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Role: lead
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
Role: lead
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Role: lead
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
Role: lead
Proton Radiation for Stage II/III Breast Cancer
Role: lead
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Role: lead
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Role: lead
All 10 trials loaded